XML 93 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2013
Revenue Accounted for 10% or More of Total Revenues

Customers whose collaborative research and development revenue accounted for 10% or more of total revenues were as follows:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2013

 

 

 

2012

 

 

 

2013

 

 

 

2012

 

Novartis AG             

 

—

 

 

 

  100

%

 

 

—

 

 

 

  100

%

Bristol-Myers Squibb Company and Pfizer Inc.             

 

  43

%

 

 

—

 

 

 

  54

%

 

 

—

 

Bayer Pharma, AG and Janssen Pharmaceuticals, Inc.             

 

  51

%

 

 

—

 

 

 

  43

%

 

 

—